Your browser doesn't support javascript.
loading
Prospective study of neuropathic pain after definitive surgery for extremity osteosarcoma in a pediatric population.
Anghelescu, Doralina L; Steen, Brenda D; Wu, Huiyun; Wu, Jianrong; Daw, Najat C; Rao, Bhaskar N; Neel, Michael D; Navid, Fariba.
Afiliación
  • Anghelescu DL; Pain Management Service, Division of Anesthesiology, Department of Pediatric Medicine, St Jude Children's Research Hospital, Memphis, Tennessee.
  • Steen BD; Department of Anesthesiology, St Jude Children's Research Hospital, Memphis, Tennessee.
  • Wu H; Department of Biostatistics, St Jude Children's Research Hospital, Memphis, Tennessee.
  • Wu J; Department of Biostatistics, St Jude Children's Research Hospital, Memphis, Tennessee.
  • Daw NC; Division of Pediatrics, MD Anderson Cancer Center, Houston, Texas.
  • Rao BN; Department of Surgery, St Jude Children's Research Hospital, Memphis, Tennessee.
  • Neel MD; St. Jude Children's Research Hospital, Memphis, Tennessee.
  • Navid F; Department of Oncology, St Jude Children's Research Hospital, Memphis, Tennessee.
Pediatr Blood Cancer ; 64(3)2017 03.
Article en En | MEDLINE | ID: mdl-27573717
ABSTRACT

BACKGROUND:

Neuropathic pain (NP) after definitive surgery for extremity osteosarcoma (OS) has not been previously characterized. This study prospectively investigates the incidence, duration, and treatment of NP in limb sparing surgery and amputation groups. PROCEDURE In patients treated for OS on a chemotherapy and definitive surgery (limb sparing vs. amputation) protocol (OS08), we prospectively collected the following data (i) demographical data (age, sex, race); (ii) NP time of onset and duration; and (iii) dose (starting, maximum) and duration of gabapentin, amitriptyline, and methadone treatment.

RESULTS:

Thirty-seven patients underwent 38 definitive surgeries limb sparing (26, 68.4%) or amputations (12, 31.6%). Localization included lower extremity (30, 81%), upper extremity (6, 16%), or pelvis (1, 3%). Thirty patients (81%) developed NP and 26 of them required NP-specific medications (87.7%). The mean [standard deviation (SD)] duration of NP was 6.5 weeks (7.2) (median 4.4, range 0.3-29.9). All 26 patients (27 surgeries) treated with NP medications received gabapentin, either as single therapy (65.4%) (17 patients, 18 surgeries), dual therapy with gabapentin and amitriptyline (five patients), or triple therapy with gabapentin, amitriptyline, and methadone (four patients). The mean starting (maximum) doses of gabapentin, amitriptyline, and methadone (mg/kg/day) were 20.2 (43.8), 0.5 (0.7), and 0.3 (0.3), respectively. The incidence and duration of NP, duration of treatment, and NP-specific dose regimens were similar in the limb sparing and the amputation groups.

CONCLUSIONS:

NP after definitive surgery for OS is frequently encountered, can persist for a significant time, and NP outcomes are similar in limb sparing and amputation groups.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Dolor Postoperatorio / Neoplasias Óseas / Osteosarcoma / Extremidades / Neuralgia Tipo de estudio: Clinical_trials / Diagnostic_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Female / Humans / Male Idioma: En Revista: Pediatr Blood Cancer Asunto de la revista: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Año: 2017 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Dolor Postoperatorio / Neoplasias Óseas / Osteosarcoma / Extremidades / Neuralgia Tipo de estudio: Clinical_trials / Diagnostic_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Female / Humans / Male Idioma: En Revista: Pediatr Blood Cancer Asunto de la revista: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Año: 2017 Tipo del documento: Article